This inventor holds 92 USPTO granted patents and 34 published patent applications, plus 10 CIPO patents and 11 EPO patents, primarily in Antiviral Compositions (CPC class A61K9-08). Top assignees: Purdue Pharma L.p., E.i. Dupont De Nemours and Company, Zhuhai Beihai Biotech Co., Ltd.. Active years: 1998-2025.
Inventors with similar research interests:
Location History:
- Belle Mead, NJ (US) (2005 - 2012)
- Wilmington, DE (US) (1998 - 2017)
- Princeton, PA (US) (2020)
- Princeton, NJ (US) (2005 - 2022)
Company Filing History:
29 out of 547 
25 out of 16,339 
13 out of 13 
Years Active: 1998-2025
Areas of Expertise:
Title: Qun Sun: Innovator in Pharmaceutical Compositions
Introduction
Qun Sun, based in Princeton, NJ, is a prolific inventor with an impressive portfolio of 60 patents. His work primarily focuses on pharmaceutical innovations, particularly in the field of drug formulations. His latest contributions to the industry demonstrate his commitment to advancing therapeutic solutions through innovative compositions.
Latest Patents
One of Qun Sun's most recent patents involves the development of neutral pH compositions of docetaxel and human serum albumin. This patent describes non-covalently bound complexes that include docetaxel and human serum albumin, together in a formulation that remains a clear aqueous solution with a solubility of at least 10 mg/ml. It details specific weight ratios for the components, ranging from about 1:50 to about 1:1000, and specifies that the pH of the final composition is maintained between 5 and 8. Such advancements are significant for improving the efficacy and stability of pharmaceutical formulations.
Career Highlights
Throughout his career, Qun Sun has made substantial contributions while working with notable companies, including Purdue Pharma L.P. and Zhuhai Beihai Biotech Co., Ltd. His innovative mindset and dedication to research are reflected in the multitude of patents that he holds, underscoring his influence in the pharmaceutical industry.
Collaborations
Qun Sun has collaborated with respected professionals in the field, notably Donald J. Kyle and Laykea Tafesse. These partnerships have further enriched his work, fostering a collaborative environment that propels innovative research and development in pharmaceuticals.
Conclusion
Qun Sun's ongoing contributions in the realm of drug formulations and his extensive patent portfolio mark him as a significant figure in pharmaceutical innovation. His dedication to developing effective and stable drug compositions continues to enhance therapeutic options available in the market, positively impacting patient care and treatment outcomes.